Edition:
India

Codexis Inc (CDXS.OQ)

CDXS.OQ on NASDAQ Stock Exchange Global Select Market

15.60USD
19 Oct 2018
Change (% chg)

$-0.22 (-1.39%)
Prev Close
$15.82
Open
$15.84
Day's High
$16.06
Day's Low
$15.56
Volume
20,592
Avg. Vol
108,821
52-wk High
$19.55
52-wk Low
$5.80

Summary

Name Age Since Current Position

Bernard Kelley

76 2016 Chairman of the Board

Thomas Baruch

79 2016 Chairman Emeritus

John Nicols

54 2012 President, Chief Executive Officer, Director

Gordon Sangster

65 2014 Chief Financial Officer, Senior Vice President

James Lalonde

57 2014 Senior Vice President, Research & Development

Pam Cheng

47 2014 Director

Kathleen Glaub

64 2014 Director

Patrick Yang

70 2014 Director

Byron Dorgan

75 2011 Independent Director

David Smith

58 2016 Independent Director

Dennis Wolf

65 2007 Independent Director

Biographies

Name Description

Bernard Kelley

Mr. Bernard J. Kelley serves as an Chairman of the Board of the Company effective November 29, 2016. He was Independent Director of Codexis, Inc., since April 2004. From 1993 to 2002, Prior to joining the Codexis Board, Mr. Kelley was President of the Merck Manufacturing Division where he was responsible for chemical, pharmaceutical and biological manufacturing and directed the activities of corporate engineering and global procurement. He also served as a member of the Merck Management Committee through his retirement in 2003. Mr. Kelley previously served as a Director of MAP Pharmaceuticals, Inc., a biotechnology company focused on developing inhalation-based therapies, as well as a Director of Aegis Analytical Corporation, an enterprise software company. He holds a B.S. in engineering from the U.S. Naval Academy.

Thomas Baruch

Mr. Thomas R. Baruch, J.D., serves as Chairman Emeritus of the Company. He was Independent Chairman of the Board of Codexis, Inc. Mr. Baruch brings to our board of directors knowledge of the biotechnology and clean technology industries as well as public company governance experience. Since April 2013, Mr. Baruch has served as partner of Formation 8, a venture capital fund, and since November 2010, Mr. Baruch has served as managing general partner of Baruch Future Ventures, LLC, a venture capital fund that he founded. Mr. Baruch is also the founder and partner emeritus of CMEA Capital, a venture capital firm that was established in 1989 as an affiliated fund of New Enterprise Associates. Mr. Baruch served as managing partner of CMEA Capital from 1989 to October 2010. Mr. Baruch currently serves as a director for various clean technology companies, including as a member of the board of directors of Calysta Energy, Inc., a renewable fuels and chemicals company; FORO Energy, a company developing a new hybrid thermal mechanical drilling technology for geothermal energy wells; Halotechnics, Inc., a thermal electricity storage company; Urban Electric Power, a developer of rechargeable battery systems; and as chairman of the board of directors of Intermolecular, Inc., a publicly traded company offering high productivity combinatorial synthesis technologies for application in the semiconductor and clean energy sectors, where he also serves on the compensation and nominating and corporate governance committees. Mr. Baruch holds a B.S. in engineering from Rensselaer Polytechnic Institute and a J.D. from Capital University.

John Nicols

Mr. John J. Nicols serves as President, Chief Executive Officer, Director of Codexis, Inc. Mr. Nicols brings to our board of directors his knowledge of Codexis as its President and Chief Executive Officer and his extensive prior management experience in the chemicals industry. Prior to that time, Mr. Nicols served in various capacities at Albemarle Corporation, a public company focused on the development, manufacture and marketing of highly engineered specialty chemicals, since he joined that company in 1990. Mr. Nicols most recently served as its Senior Vice President, Strategic Development and Catalysts, from March 2012 to June 2012. Mr. Nicols previously served as its Vice President, Catalysts from January 2007 to February 2012, its Vice President, Fine Chemistry from June 2002 to December 2006, its Division Vice President, Global Flame Retardants business from February 1999 through June 2002 and its Asia Pacific Business Director for the Bromine Chemicals business, based in Tokyo, Japan, from 1995 to 1998. Prior to his time with Albemarle Corporation, Mr. Nicols worked for three years in manufacturing and research and development for Hercules, Inc. Mr. Nicols has served on the board of directors of BayBio, Northern California Life Sciences Association, a non-profit organization, since January 2014, and on the board of directors, scientific committee and nominating committee of the Solve ME/CFS Initiative, a non-profit organization, since January 2015. Mr. Nicols received a B.S. in Chemical Engineering from the Polytechnic Institute of New York University and an M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology.

Gordon Sangster

Mr. Gordon T. Sangster is Chief Financial Officer, Senior Vice President of the Company, effective August 18, 2014. Mr. Sangster served as Chief Financial Officer of Nitinol Devices & Components, a private medical device manufacturer, from October 2011 until July 2014. Prior to that role, Mr. Sangster was Chief Financial Officer of ITC Nexus-Dx, a private medical device company that focused on point-of-care diagnostics, from October 2010 to July 2011. From November 2007 to October 2010, Mr. Sangster was Chief Financial Officer of Micrus Endovascular, a publicly traded medical device company that was acquired by Johnson & Johnson. From 2006 to 2007, Mr. Sangster was also Chief Financial Officer of HemoSense, Inc., a publicly traded medical device company that was acquired by Alere. Prior to that role, Mr. Sangster was Chief Financial Officer of AP Pharma, a publicly traded biotechnology company, from 2000 to 2006. Prior to his Chief Financial Officer roles, Mr. Sangster held roles of increasing responsibility in finance at AP Pharma, Raychem, and CooperVision. Mr. Sangster is a member of the Institute of Chartered Accountants in England and Wales.

James Lalonde

Mr. James J. Lalonde is Senior Vice President, Research & Development of the Company since February 2014. He served as Codexis’ Vice President, Research and Development from December 2005 to February 2014. Dr. Lalonde joined Codexis in July 2004 as Director, Biocatalysis and Chemical Development. Prior to joining Codexis, Dr. Lalonde worked at Altus Biologics, Inc. and Vista Chemical Co. He is also the co-author on a variety of research publications and a co-inventor on numerous patents. Dr. Lalonde holds an Honours B.S. from Lakehead University and a Ph.D. in Organic Chemistry from Texas A&M University.

Pam Cheng

Ms. Pam P. Cheng is appointed as Director of the Company., effective October 30, 2014. Ms. Cheng brings to our board of directors experience in pharmaceutical manufacturing and conducting business in Asia, as well as senior management and financial operations experience. Ms. Cheng has served as the Executive Vice President, Operations and IT for AstraZeneca plc, a publicly-traded multinational pharmaceutical and biologics company, since June 2015. Previously, Ms. Cheng was a 17-year veteran of Merck and most recently served as President of MSD China, Merck’s subsidiary in China. Prior to serving as President of MSD China, Ms. Cheng served as Senior Vice President, Global Supply Chain Management for Merck in New Jersey, with overall end-to-end supply chain oversight for its human health, vaccines, and consumer care businesses globally. Before Merck, Ms. Cheng held operational roles at GAF Chemicals and UOP/Union Carbide. Ms. Cheng received an M.B.A. in Marketing from Pace University in New York and her Bachelor and Masters of Chemical Engineering from the Stevens Institute of Technology in New Jersey. She has also earned Six Sigma Executive Belt Certification.

Kathleen Glaub

Ms. Kathleen Sereda Glaub has been appointed as Director of Codexis, Inc. Ms. Glaub brings to our board of directors experience in company-building and business strategy at drug development and technology companies. Ms. Glaub currently acts a strategic advisor to several biotechnology companies. From August 2014 until its acquisition by Merck in July 2016, Ms. Glaub served as Chief Executive Officer of Afferent Pharmaceuticals, which was a clinical-stage biotechnology company developing treatments for respiratory and urologic disorders and chronic pain. Ms. Glaub also served on the board of directors of Afferent from 2013 through 2016. Previously, from November 2001 to May 2013, Ms. Glaub served as President of Plexxikon Inc., a biopharmaceutical company that was acquired by Daiichi Sankyo in 2011. Prior to Plexxikon, Ms. Glaub served as Chief Financial Officer for Cell Genesys, Inc., a biotechnology company. Prior to Cell Genesys, Ms. Glaub served as the Treasurer of Genentech, Inc., a biotechnology company (“Genentech”), and held various financial and treasury roles at Intel Corporation. In January 2017, she joined the advisory board for Bailard Healthcare Fund. Ms. Glaub received her B.A. from the University of California, Berkeley, and her M.B.A. from Northwestern University.

Patrick Yang

Dr. Patrick Y. Yang, Ph.D., is Director of the Codexis, Inc. Dr. Yang brings to our board of directors significant experience in pharmaceuticals manufacturing, engineering, technology and supply chain management. From January 2010 to March 2013, Dr. Yang served as Head of Global Technical Operations for F. Hoffmann-La Roche Ltd. where he was responsible for Roche's pharmaceutical manufacturing, process development, engineering, quality, regulatory, supply chain and procurement. Before joining Roche, Dr. Yang worked for Genentech Inc., where he most recently served as Executive Vice President of Product Operations. Prior to joining Genentech, Dr. Yang worked for Merck & Co., where he most recently served as Vice President of Supply Chain Management. He has also previously worked at General Electric Co. and Life Systems, Inc. Dr. Yang currently serves on the board of directors of Tesoro Corporation, a public independent refining and marketing company, where he has served on the governance committee since June 2013 and the environment, health, safety and security committee since December 2010 and previously served on the audit committee from December 2010 to June 2013. He previously served on the board of TaiMed, Inc. Dr. Yang earned a Bachelor of Science in Engineering from the National Chiaotung University in Taiwan, a Master of Science in Electrical Engineering from the University of Cincinnati and a Ph.D. in engineering from the Ohio State University.

Byron Dorgan

Senator Byron L. Dorgan serves as an Independent Director of Codexis, Inc. since February 2011. Mr. Dorgan brings to our board of directors experience in economic issues, policy making, health care and government affairs. Mr. Dorgan represented the State of North Dakota in the United States Senate from 1992 to January 2011, when he retired. Prior to serving in the United States Senate, Mr. Dorgan served in the United States House of Representatives from 1981 to 1992. During his time in the United States Senate, Mr. Dorgan served in the United States Senate Leadership, first as Assistant Democratic Floor Leader and then as Chairman of the Democratic Policy Committee. He also served as the Chairman of the Committee on Indian Affairs and was the senior Senator on the Appropriations, Energy and Commerce Committees. Prior to being elected to the United States House of Representatives, Mr. Dorgan served as North Dakota State Tax Commissioner from 1969 until 1980. Mr. Dorgan is a New York Times bestselling author of four books, including Take this Job and Ship It: How Corporate Greed and Brain-Dead Politics Are Selling Out America, Reckless! How Debt, Deregulation and Dark Money Nearly Bankrupted America, Blowout and Gridlock. Mr. Dorgan holds a B.S. from the University of North Dakota and an M.B.A. from the University of Denver.

David Smith

Mr. David V. Smith is Independent Director of the Company since March 2016. Mr. Smith brings to our board of directors extensive experience in financial management, corporate finance and corporate governance. Mr. Smith served as Chief Operating Officer of IntegenX, a privately held company focused on rapid DNA identification technology, until its acquisition by Thermo Fisher Scientific in March 2018. Prior to IntegenX, he was Executive Vice President and Chief Financial Officer of Thoratec Corporation, a publicly-traded company focused on the development of advanced therapy options for the treatment of heart disease, from December 2006 until July 2011. Prior to joining Thoratec in 2006, Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation, which he joined in 1999, and where he held a number of positions of increasing responsibility, including Vice President, Principal Accounting Officer and Controller, and Vice President of Finance. Mr. Smith served as the Vice President of Finance and Chief Financial Officer at Anergen Incorporated from 1997 to 1999. From 1988 to 1997, Mr. Smith served in various financial management positions with Genentech, Inc., both in the United States and Europe. He previously held finance positions at Syntex

Dennis Wolf

Mr. Dennis P. Wolf serves as an Independent Director of Codexis, Inc since December 2007. Mr. Wolf brings to our board of directors extensive experience in financial management, corporate finance and public company corporate governance. Mr. Wolf served as Chief Financial Officer of DataStax, Inc., a private software company, from November 2013 to February 2017. Prior to DataStax, Mr. Wolf served as Executive Vice President and Chief Financial Officer of Fusion-io Multisystems, a computer hardware and software company, from November 2009 to October 2013. Prior to Fusion-io, Mr. Wolf served as Executive Vice President and Chief Financial Officer of MySQL AB. Mr. Wolf has also held financial management positions for public high technology companies including Apple Computer, Inc., Centigram Communications, Inc., Credence Systems Corporation, Omnicell, Inc., Redback Networks Inc. and Sun Microsystems, Inc. Mr. Wolf has been a director and chair of the audit committee for other public companies including Quantum Corporation, Avanex Corporation, Bigband Networks, Komag, Inc., Registry Magic, Inc. and Vitria Technology, Inc., and served as a director of Exponential Interactive, Inc. He holds a B.A. from the University of Colorado and an M.B.A. from the University of Denver.

Basic Compensation

Name Fiscal Year Total

Bernard Kelley

212,931

Thomas Baruch

164,617

John Nicols

3,377,200

Gordon Sangster

1,342,890

James Lalonde

1,160,940

Pam Cheng

169,997

Kathleen Glaub

147,443

Patrick Yang

159,997

Byron Dorgan

184,997

David Smith

157,008

Dennis Wolf

162,986
As Of  31 Dec 2017